[4th Hungarian Breast Cancer Consensus Conference - Radiotherapy guidelines].

Q4 Medicine Magyar onkologia Pub Date : 2020-12-14 Epub Date: 2020-11-30
Csaba Polgár, Zsuzsanna Kahán, András Csejtei, Gabriella Gábor, László Landherr, László Mangel, Árpád Mayer, János Fodor
{"title":"[4th Hungarian Breast Cancer Consensus Conference - Radiotherapy guidelines].","authors":"Csaba Polgár,&nbsp;Zsuzsanna Kahán,&nbsp;András Csejtei,&nbsp;Gabriella Gábor,&nbsp;László Landherr,&nbsp;László Mangel,&nbsp;Árpád Mayer,&nbsp;János Fodor","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The radiotherapy (RT) expert panel revised and updated the RT guidelines accepted in 2016 at the 3rd Hungarian Breast Cancer Consensus Conference based on new scientific evidence. Radiotherapy after breast-conserving surgery (BCS) is indicated in ductal carcinoma in situ (St. 0), as RT decreases the risk of local recurrence (LR) by 50-60%. In early stage (St. I-II) invasive breast cancer RT remains a standard treatment following BCS. However, in elderly (≥70 years) patients with stage I, hormone receptor positive tumour hormonal therapy without RT can be considered. Hypofractionated whole breast irradiation (WBI) and for selected cases accelerated partial breast irradiation are validated treatment alternatives of conventional WBI. Following mastectomy RT significantly decreases the risk of LR and improves overall survival of patients having 1 to 3 or ≥4 positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be substituted with axillary RT. After neoadjuvant chemotherapy (NAC) followed by BCS WBI is mandatory, while after NAC followed by mastectomy locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status.</p>","PeriodicalId":18175,"journal":{"name":"Magyar onkologia","volume":"64 4","pages":"371-383"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magyar onkologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/11/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The radiotherapy (RT) expert panel revised and updated the RT guidelines accepted in 2016 at the 3rd Hungarian Breast Cancer Consensus Conference based on new scientific evidence. Radiotherapy after breast-conserving surgery (BCS) is indicated in ductal carcinoma in situ (St. 0), as RT decreases the risk of local recurrence (LR) by 50-60%. In early stage (St. I-II) invasive breast cancer RT remains a standard treatment following BCS. However, in elderly (≥70 years) patients with stage I, hormone receptor positive tumour hormonal therapy without RT can be considered. Hypofractionated whole breast irradiation (WBI) and for selected cases accelerated partial breast irradiation are validated treatment alternatives of conventional WBI. Following mastectomy RT significantly decreases the risk of LR and improves overall survival of patients having 1 to 3 or ≥4 positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be substituted with axillary RT. After neoadjuvant chemotherapy (NAC) followed by BCS WBI is mandatory, while after NAC followed by mastectomy locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[第四届匈牙利乳腺癌共识会议-放疗指南]。
放疗(RT)专家小组根据新的科学证据修订和更新了2016年第三届匈牙利乳腺癌共识会议上接受的放疗指南。保乳手术(BCS)后放疗适用于导管原位癌(St. 0),因为RT可降低局部复发(LR)的风险50-60%。早期(St. I-II期)浸润性乳腺癌放疗仍然是BCS后的标准治疗。然而,在老年(≥70岁)I期患者中,可以考虑激素受体阳性肿瘤激素治疗而不进行RT。低分割全乳照射(WBI)和某些病例加速部分乳房照射是传统WBI的有效治疗选择。乳房切除术后RT显著降低LR的风险,提高1 - 3或≥4个阳性腋窝淋巴结患者的总生存率。在有1 ~ 2个前哨淋巴结阳性的患者中,可选择腋窝清扫术代替腋窝放疗。在新辅助化疗(NAC)后再行BCS后,WBI是强制性的,而在NAC后再行乳房切除术,对于初始III-IV期和ypN1期腋窝状态的患者,应给予局部局部放疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Magyar onkologia
Magyar onkologia Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
30
期刊最新文献
[The expanding possibilities of immuno-oncology treatments]. [Therapeutic drug monitoring for supporting oncological treatments: a new era begins]. [The role of classic serum tumor markers in the diagnosis and treatment monitoring of solid tumors in adults]. [Current therapeutic and familial implications of the genetic background of prostate cancer]. [Paraneoplastic endocrine syndromes: clinical picture and laboratory diagnostics].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1